WORK PACKAGE 11
From HTA results to guidance implementation: paving the way
Objectives
-
Identify and categorise technologies offering prospects for efficiency gains outside incremental innovations (higher quality/higher costs)
-
Clarify under which conditions decremental cost-effectiveness is acceptable for collective health gains
-
Develop a tool-box for use at a local level for HTA projects to maximise those health gains
Methodology
-
Systematic search of clinical trials registries and published literature to identify decrementally cost-effective programmes, as for example non-drug interventions or non-inferiority trials
-
Conduct a systematic enquiry into the willingness of stakeholders (namely patients, professionals, decision makers, tax payers) to accept a decremental efficacy
-
A toolbox and guidance for HTA agencies to go beyond cost-effective comparators in their assessments and recommendations
Outcomes
-
The algorithm used to identify the decrementally cost effective programmes will be published as well as a state of art analysis in Europe of candidate technologies
-
An analysis of the obstacles and potential drivers for acceptance of decremental efficacy using a political economy approach of stakeholders’ perspectives
-
The toolbox will provide specific methodological and policy guidance concerning the evaluation and implementation of candidate technologies
Research Update
January 2019 – IMPACT HTA 2nd Project Meeting (Presentation PDF)
November 2019 – Budget impact analysis of triple therapy after failure of methotrexate for the treatment of rheumatoid arthritis in France – ISPOR Europe (weblink)
November 2019 - Annual cost of patients undergoing a total knee replacement in France – ISPOR Europe (weblink)
Leads
Paris School of Economics – Hospinnomics
Assistance Publique-Hôpitaux de Paris
Principal Investigators
